TWiV 1044: Clinical update with Dr. Daniel Griffin

In his weekly clinical update, Dr. Griffin discusses the immunogenicity and reactogenicity of coadministration of COVID-19 and Influenza vaccines, interim effectiveness estimates of 2023 southern hemisphere influenza vaccines in preventing Influenza-associated hospitalizations, genome-wide association study of susceptibility to RSV hospitalization in young children Subscribe (free): Apple Podcasts , Google Podcasts , RSS , email Become a patron of TWiV! Links for this episode Immunogenicity and reactogenicity of coadministration of COVID-19 and Influenza vaccines (JAMA) Effectiveness estimates of Influenza vaccines in preventing associated hospitalizations (CDC) Genome-wide association study of susceptibility to RSV hospitalization in children (JID) Performance of rapid antigen tests to detect SARS-CoV-2 infection (AIN) Safety and immunogenicity of XBB.1.5-containing mRNA vaccines (medRxiv) C.D.C. director explains why you should get the latest Covid booster (Nytimes) Optimal duration of systemic corticosteroids in COVID-19 treatment (OFID) Timing and predictors of loss of infectivity among healthcare workers with COVID-19 (CID) Effect of famotidine on cognitive and behavioral dysfunctions induced in post-COVID-19 infection (JPR) Contribute to our Floating Doctors fundraiser at PWB Letters read on TWiV 1044 Dr. Griffin's COVID treatment summary ( pdf ) Timestamps by Jolene . Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]